In the second episode of Cleary Gottlieb’s Antitrust Review podcast, a panel of Cleary Gottlieb partners discuss the achievements to
The Italian Parliament Approves Competition Law Reform
On August 5, 2022, the Italian Parliament adopted Law No. 118, the “2021 Annual Competition Law” (the “ACL”). The ACL, which will enter into force on August 27, 2022, amends the Italian Competition Law (Law No. 287/90) in various respects.
Competition Appeal Tribunal Sets Aside CMA’s First Antitrust Fine for Most Favoured Nation Clauses in its Compare the Market Decision
The UK Competition Appeal Tribunal (CAT) on 8 August 2022 set aside a £17.9 million fine against price comparison website Compare The Market, criticising the Competition and Markets Authority’s (CMA) legal and evidential assessment of the case. The CAT found that the CMA’s “anecdotal evidence”[1] failed to prove that Compare The Market kept home insurance premiums artificially high by using most favoured nation clauses (MFNs) in its contracts with insurance providers. The CMA has said it is disappointed with the CAT’s ruling and is considering its options, including a potential appeal.
Chambers Merger Control 2022 Global Practice Guide: UK
Cleary Gottlieb partners Nicholas Levy, Paul Gilbert, and Jackie Holland and associate Courtney Olden co-authored the “UK” chapter of the
New UK Framework for Vertical Agreements Finalised
Thank You for the Music – CMA Publishes Update in Music and Streaming Study
On 26 July the CMA published an Update Paper in its music and streaming market study (launched 27 January).[1] The Update Paper sets out the CMA’s preliminary findings halfway through its study into how well competition works in music streaming.
Unfair Play: UK CMA Fines Pharmaceutical Companies for Excessive Prices
The UK Competition and Markets Authority (CMA) last week fined pharmaceutical companies Pfizer and Flynn £63 million and £6.7 million for engaging in excessive pricing. In the CMA’s view, the companies charged unfairly high prices for Phenytoin capsules, a genericised anti-epilepsy drug, in violation of competition law.
The Dominance and Monopolies Review – 10th Edition
Cleary Gottlieb partners Matteo Beretta, Frédéric de Bure, Maurits Dolmans, Paul Gilbert, Francisco Enrique González-Díaz, Thomas Graf, Henry Mostyn, Romina
Antitrust Review Episode 1: In Conversation With Andrea Coscelli
Welcome to Cleary Gottlieb’s Antitrust Review – a podcast focused on antitrust enforcement, policy and practice.
In a complex and
China’s Delegated Review of Certain Merger Control Filings
On July 15, 2022, China’s antitrust authority SAMR announced a three-year pilot program beginning August 1, 2022 to delegate the review of certain simplified-procedure merger filings that the agency currently handles on its own, to five of its local branches (“AMRs”) in Beijing, Shanghai, Guangdong, Chongqing, and Shaanxi. Each of the five local AMRs will be responsible for a specific geographic area (“Territory”) within China. This is the first step to implement China’s “categorized and classified” merger control review regime under the new Anti-Monopoly Law.[1]